Hanauer SB, Sands BE, Schreiber S, Danese S, et al. Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials. Gastroenterology 2024 May 22:S0016-5085(24)04918.
PMID: 38788861